What is NDC 82491-025?

82491-025 is the product NDC for Lytenava (bevacizumab-vikg), Bevacizumab 1.25 mg/1 injection, listed with the FDA by Outlook Therapeutics, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Outlook Therapeutics, Inc., NDC labeler code 82491. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Lytenava?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Lytenava NDC 82491-025 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)82491-025Labeler and product segments. Claims need a package NDC.

Product NDC at billing width82491-0025Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
82491-025-10	82491002510	1 VIAL, GLASS in 1 CARTON (82491-025-10) / 1 INJECTION in 1 VIAL, GLASSMarketed from Jul 16, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lytenava
Generic name (nonproprietary): bevacizumab-vikg
Active ingredients: Bevacizumab — 1.25 mg/1
Dosage form: Injection
Route: Intravitreal
Labeler: Outlook Therapeutics, Inc.NDC labeler code 82491
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761320
Marketing start: Jul 16, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Vascular Endothelial Growth Factor Inhibitors (Mechanism)Vascular Endothelial Growth Factor-directed Antibody Interactions (Mechanism)
Identifiers: Product ID 82491-025_c4cac030-d1d8-4bb1-a38c-c1e2e91f002dSPL ID c4cac030-d1d8-4bb1-a38c-c1e2e91f002d
Pharmacologic class: Vascular Endothelial Growth Factor Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N482491002510 followed by a unit qualifier and the quantity

Package 82491-0025-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.

About NDC 82491-025

What is NDC 82491-025?: 82491-025 is the product NDC for Lytenava (bevacizumab-vikg), Bevacizumab 1.25 mg/1 injection, listed with the FDA by Outlook Therapeutics, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Lytenava (Bevacizumab-vikg).
What is the active ingredient?: Bevacizumab.
Who is the labeler?: Outlook Therapeutics, Inc., NDC labeler code 82491. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Lytenava?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Lytenava (Bevacizumab-vikg) NDC 82491-025